An oncovirus is a virus that can cause cancer. This term originated from studies of acutely transforming retroviruses in the 1950–60s, when the term "oncornaviruses" was used to denote their RNA virus origin. With the letters "RNA" removed, it now refers to any virus with a DNA or RNA genome causing cancer and is synonymous with "tumor virus" or "cancer virus". The vast majority of human and animal viruses do not cause cancer, probably because of longstanding co-evolution between the virus and its host. Oncoviruses have been important not only in epidemiology, but also in investigations of cell cycle control mechanisms such as the retinoblastoma protein.
The World Health Organization's International Agency for Research on Cancer estimated that in 2002, infection caused 17.8% of human cancers, with 11.9% caused by one of seven viruses. A 2020 study of 2,658 samples from 38 different types of cancer found that 16% were associated with a virus. These cancers might be easily prevented through vaccination (e.g., papillomavirus vaccines), diagnosed with simple blood tests, and treated with less-toxic antiviral compounds.
Generally, tumor viruses cause little or no disease after infection in their hosts, or cause non-neoplastic diseases such as acute hepatitis for hepatitis B virus or mononucleosis for Epstein–Barr virus. A minority of persons (or animals) will go on to develop cancers after infection. This has complicated efforts to determine whether or not a given virus causes cancer. The well-known Koch's postulates, 19th-century constructs developed by Robert Koch to establish the likelihood that Bacillus anthracis will cause anthrax disease, are not applicable to viral diseases. Firstly, this is because viruses cannot truly be isolated in pure culture—even stringent isolation techniques cannot exclude undetected contaminating viruses with similar density characteristics, and viruses must be grown on cells. Secondly, asymptomatic virus infection and carriage is the norm for most tumor viruses, which violates Koch's third principle. Relman and Fredericks have described the difficulties in applying Koch's postulates to virus-induced cancers. Finally, the host restriction for human viruses makes it unethical to experimentally transmit a suspected cancer virus. Other measures, such as A. B. Hill's criteria, are more relevant to cancer virology but also have some limitations in determining causality.
Tumor viruses come in a variety of forms: Viruses with a DNA genome, such as adenovirus, and viruses with an RNA genome, like the hepatitis C virus (HCV), can cause cancers, as can retroviruses having both DNA and RNA genomes (Human T-lymphotropic virus and hepatitis B virus, which normally replicates as a mixed double and single-stranded DNA virus but also has a retroviral replication component). In many cases, tumor viruses do not cause cancer in their native hosts but only in dead-end species. For example, adenoviruses do not cause cancer in humans but are instead responsible for colds, conjunctivitis and other acute illnesses. They only become tumorigenic when infected into certain rodent species, such as Syrian hamsters. Some viruses are tumorigenic when they infect a cell and persist as circular episomes or plasmids, replicating separately from host cell DNA (Epstein–Barr virus and Kaposi's sarcoma-associated herpesvirus). Other viruses are only carcinogenic when they integrate into the host cell genome as part of a biological accident, such as polyomaviruses and papillomaviruses.
A direct oncogenic viral mechanism involves either insertion of additional viral oncogenic genes into the host cell or to enhance already existing oncogenic genes (proto-oncogenes) in the genome. For example, it has been shown that vFLIP and vCyclin interfere with the TGF-β signaling pathway indirectly by inducing oncogenic host mir17-92 cluster. Indirect viral oncogenicity involves chronic nonspecific inflammation occurring over decades of infection, as is the case for HCV-induced liver cancer. These two mechanisms differ in their biology and epidemiology: direct tumor viruses must have at least one virus copy in every tumor cell expressing at least one protein or RNA that is causing the cell to become cancerous. Because foreign virus antigens are expressed in these tumors, persons who are immunosuppressed such as AIDS or transplant patients are at higher risk for these types of cancers. Chronic indirect tumor viruses, on the other hand, can be lost (at least theoretically) from a mature tumor that has accumulated sufficient mutations and growth conditions (hyperplasia) from the chronic inflammation of viral infection. In this latter case, it is controversial but at least theoretically possible that an indirect tumor virus could undergo "hit-and-run" and so the virus would be lost from the clinically diagnosed tumor. In practical terms, this is an uncommon occurrence if it does occur.
Timeline of discovery
- 1908: Vilhelm Ellerman and Olaf Bang at the University of Copenhagen demonstrated that avian sarcoma leukosis virus could be transmitted between chickens after cell-free filtration and subsequently cause leukemia.
- 1910: Peyton Rous at the Rockefeller University extended Bang and Ellerman's experiments to show cell-free transmission of a solid tumor sarcoma to chickens (now known as Rous sarcoma). The reasons why chickens are so receptive to such transmission may involve unusual characteristics of stability or instability as they relate to endogenous retroviruses.
- 1933: Richard Edwin Shope discovered cottontail rabbit papillomavirus or Shope papillomavirus, the first mammalian tumor virus.
- 1936: John J. Bittner identified the mouse mammary tumor virus, an "extrachromosomal factor" (i.e. virus) that could be transmitted between laboratory strains of mice by breast feeding. This was an extension of work on murine breast cancer caused by a transmissible agent as early as 1915, by A.F. Lathrop and L. Loeb.
- 1953: Ludwik Gross, working at the Bronx VA Medical Center, isolated murine polyomavirus, which caused a variety of salivary gland and other tumors in specific strains of newborn mice, subsequently confirmed by Sarah Stewart and Bernice Eddy.
- 1957: Charlotte Friend discovered the Friend virus, a strain of murine leukemia virus capable of causing cancers in immunocompetent mice. Though her findings received significant backlash, they were eventually accepted by the field and cemented the validity of viral oncogenesis.
- 1961: Eddy discovered simian vacuolating virus 40 (SV40) at the NIH. Hillman and Sweet at Merck Laboratory also confirmed the existence of a rhesus macaque virus contaminating cells used to make Salk and Sabin polio vaccines. Several years later, it was shown to cause cancer in Syrian hamsters, raising concern about possible human health implications. Scientific consensus now strongly agrees that this is not likely to cause human cancer.
- 1964: Anthony Epstein, Bert Achong and Yvonne Barr identified the first human oncovirus from Burkitt's lymphoma cells. A herpesvirus, this virus is formally known as human herpesvirus 4 but more commonly called Epstein–Barr virus or EBV.
- mid 1960s: Baruch Blumberg first physically isolated and characterized Hepatitis B while at NIH and later Fox Chase Laboratory, receiving the 1976 Nobel Prize in Medicine or Physiology. Although this agent was the clear cause of hepatitis and might contribute to liver cancer hepatocellular carcinoma, this link was not firmly established until epidemiologic studies were performed in the 1980s by R. Palmer Beasley and others.
- 1980: Human T-lymphotropic virus 1 (HTLV I), the first human retrovirus, was discovered by Bernard Poiesz and Robert Gallo at NIH, and independently by Mitsuaki Yoshida and coworkers in Japan.
- 1984–86: Harald zur Hausen and Lutz Gissman discovered HPV16 and HPV18, which together are responsible for approximately 70% of cervical cancers. For the discovery that human papillomaviruses (HPV) cause human cancer, zur Hausen shared the 2008 Nobel Prize in Medicine or Physiology.
- 1987: Hepatitis C virus (HCV) was discovered by panning a cDNA library made from diseased tissues for foreign antigens recognized by patient sera. This work was performed by Michael Houghton at Chiron, a biotechnology company, and D. W. Bradley at the CDC. Controversy erupted when Chiron claimed all rights to the discovery although the work had been performed under contract with the CDC using Bradley's materials and ideas. Eventually, this was amicably settled. HCV was subsequently shown to be a major contributor to liver cancer (hepatocellular carcinoma) worldwide.
- 1994: Patrick S. Moore and Yuan Chang (a husband and wife team  then at Columbia University), working together with Frank Lee and Ethel Cesarman, isolated Kaposi's sarcoma-associated herpesvirus (KSHV or HHV8) using representational difference analysis. This search was prompted by work from V. Beral, T. Peterman and H. Jaffe, who inferred from the epidemic of Kaposi's sarcoma among patients with AIDS that this cancer must be caused by another infectious agent besides HIV, and that this was likely to be a second virus. Subsequent studies revealed that KSHV is the "KS agent" and is responsible for the epidemiologic patterns of KS and related cancers.
- 2008: Chang and Moore, now at the University of Pittsburgh Cancer Institute, developed a new method to identify cancer viruses based on computer subtraction of human sequences from a tumor transcriptome, called digital transcriptome subtraction (DTS). DTS was used to isolate DNA fragments of Merkel cell polyomavirus from a Merkel cell carcinoma and it is now believed that this virus causes 70–80% of these cancers. This is the first polyomavirus to be well-established as the cause for a human cancer.
The theory that cancer could be caused by a virus began with the experiments of Oluf Bang and Vilhelm Ellerman in 1908 who first show that avian erythroblastosis (a form of chicken leukemia) could be transmitted by cell-free extracts. This was subsequently confirmed for solid tumors in chickens in 1910-1911 by Peyton Rous, and for liquid cancer in mice by Charlotte Friend.
By the early 1950s, it was known that viruses could remove and incorporate genes and genetic material in cells. It was suggested that such types of viruses could cause cancer by introducing new genes into the genome. Genetic analysis of mice infected with Friend virus confirmed that retroviral integration could disrupt tumor suppressor genes, causing cancer. Subsequently, many viral oncogenes were subsequently discovered and identified to cause cancer.
The main viruses associated with human cancers are human papillomavirus, hepatitis B and hepatitis C virus, Epstein–Barr virus, human T-lymphotropic virus, Kaposi's sarcoma-associated herpesvirus (KSHV) and Merkel cell polyomavirus. Experimental and epidemiological data imply a causative role for viruses and they appear to be the second most important risk factor for cancer development in humans, exceeded only by tobacco usage. The mode of virally induced tumors can be divided into two, acutely transforming or slowly transforming. In acutely transforming viruses, the viral particles carry a gene that encodes for an overactive oncogene called viral-oncogene (v-onc), and the infected cell is transformed as soon as v-onc is expressed. In contrast, in slowly transforming viruses, the virus genome is inserted, especially as viral genome insertion is an obligatory part of retroviruses, near a proto-oncogene in the host genome. The viral promoter or other transcription regulation elements in turn cause overexpression of that proto-oncogene, which in turn induces uncontrolled cellular proliferation. Because viral genome insertion is not specific to proto-oncogenes and the chance of insertion near that proto-oncogene is low, slowly transforming viruses have very long tumor latency compared to acutely transforming viruses, which already carry the viral oncogene.
Hepatitis viruses, including hepatitis B and hepatitis C, can induce a chronic viral infection that leads to liver cancer in 0.47% of hepatitis B patients per year (especially in Asia, less so in North America), and in 1.4% of hepatitis C carriers per year. Liver cirrhosis, whether from chronic viral hepatitis infection or alcoholism, is associated with the development of liver cancer, and the combination of cirrhosis and viral hepatitis presents the highest risk of liver cancer development. Worldwide, liver cancer is one of the most common, and most deadly, cancers due to a huge burden of viral hepatitis transmission and disease.
Through advances in cancer research, vaccines designed to prevent cancer have been created. The hepatitis B vaccine is the first vaccine that has been established to prevent cancer (hepatocellular carcinoma) by preventing infection with the causative virus. In 2006, the U.S. Food and Drug Administration approved a human papilloma virus vaccine, called Gardasil. The vaccine protects against four HPV types, which together cause 70% of cervical cancers and 90% of genital warts. In March 2007, the US Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) officially recommended that females aged 11–12 receive the vaccine, and indicated that females as young as age 9 and as old as age 26 are also candidates for immunization.
DNA oncoviruses typically impair two families of tumor suppressor proteins: tumor proteins p53 and the retinoblastoma proteins (Rb). It is evolutionarily advantageous for viruses to inactivate p53 because p53 can trigger cell cycle arrest or apoptosis in infected cells when the virus attempts to replicate its DNA. Similarly, Rb proteins regulate many essential cell functions, including but not limited to a crucial cell cycle checkpoint, making them a target for viruses attempting to interrupt regular cell function.
While several DNA oncoviruses have been discovered, three have been studied extensively. Adenoviruses can lead to tumors in rodent models but do not cause cancer in humans; however, they have been exploited as delivery vehicles in gene therapy for diseases such as cystic fibrosis and cancer. Simian virus 40 (SV40), a polyomavirus, can cause tumors in rodent models but is not oncogenic in humans. This phenomenon has been one of the major controversies of oncogenesis in the 20th century because an estimated 100 million people were inadvertently exposed to SV40 through polio vaccines. The human papillomavirus-16 (HPV-16) has been shown to lead to cervical cancer and other cancers, including head and neck cancer. These three viruses have parallel mechanisms of action, forming an archetype for DNA oncoviruses. All three of these DNA oncoviruses are able to integrate their DNA into the host cell, and use this to transcribe it and transform cells by bypassing the G1/S checkpoint of the cell cycle.
DNA oncoviruses transform infected cells by integrating their DNA into the host cell’s genome. The DNA is believed to be inserted during transcription or replication, when the two annealed strands are separated. This event is relatively rare and generally unpredictable; there seems to be no deterministic predictor of the site of integration. After integration, the host’s cell cycle loses regulation from Rb and p53, and the cell begins cloning to form a tumor.
Rb and p53 regulate the transition between G1 and S phase, arresting the cell cycle before DNA replication until the appropriate checkpoint inputs, such as DNA damage repair, are completed. p53 regulates the p21 gene, which produces a protein which binds to the Cyclin D-Cdk4/6 complex. This prevents Rb phosphorylation and prevents the cell from entering S phase. In mammals, when Rb is active (unphosphorylated), it inhibits the E2F family of transcription factors, which regulate the Cyclin E-Cdk2 complex, which inhibits Rb, forming a positive feedback loop, keeping the cell in G1 until the input crosses a threshold. To drive the cell into S phase prematurely, the viruses must inactivate p53, which plays a central role in the G1/S checkpoint, as well as Rb, which, though downstream of it, is typically kept active by a positive feedback loop.
Inactivation of p53
Viruses employ various methods of inactivating p53. The adenovirus E1B protein (55K) prevents p53 from regulating genes by binding to the site on p53 which binds to the genome. In SV40, the large T antigen (LT) is an analogue; LT also binds to several other cellular proteins, such as p107 and p130, on the same residues. LT binds to p53’s binding domain on the DNA (rather than on the protein), again preventing p53 from appropriately regulating genes. HPV instead degrades p53: the HPV protein E6 binds to a cellular protein called the E6-associated protein (E6-AP, also known as UBE3A), forming a complex which causes the rapid and specific ubiquitination of p53.
Inactivation of Rb
Rb is inactivated (thereby allowing the G1/S transition to progress unimpeded) by different but analogous viral oncoproteins. The adenovirus early region 1A (E1A) is an oncoprotein which binds to Rb and can stimulate transcription and transform cells. SV40 uses the same protein for inactivating Rb, LT, to inactivate p53. HPV contains a protein, E7, which can bind to Rb in much the same way. Rb can be inactivated by phosphorylation, or by being bound to a viral oncoprotein, or by mutations—mutations which prevent oncoprotein binding are also associated with cancer.
DNA oncoviruses typically cause cancer by inactivating p53 and Rb, thereby allowing unregulated cell division and creating tumors. There may be many different mechanisms which have evolved separately; in addition to those described above, for example, the Hepatitis B virus (an RNA virus) inactivates p53 by sequestering it in the cytoplasm.
SV40 has been well studied and does not cause cancer in humans, but a recently discovered analogue called Merkel cell polyomavirus has been associated with Merkel cell carcinoma, a form of skin cancer. The Rb binding feature is believed to be the same between the two viruses.
This section does not cite any sources. (July 2020) (Learn how and when to remove this template message)
In the 1960s, the replication process of RNA virus was believed to be similar to other single-stranded RNA. Single-stranded RNA replication involves RNA-dependent RNA synthesis which meant that virus-coding enzymes would make partial double-stranded RNA. This belief was proven to be incorrect because there were no double-stranded RNA found in the retrovirus cell. In 1964, Howard Temin proposed a provirus hypothesis, but shortly after reverse transcription in the retrovirus genome was discovered.
Description of virus
All retroviruses have three major coding domains; gag, pol and env. In the gag region of the virus, the synthesis of the internal virion proteins are maintained which make up the matrix, capsid and nucleocapsid proteins. In pol, the information for the reverse transcription and integration enzymes are stored. In env, it is derived from the surface and transmembrane for the viral envelope protein. There is a fourth coding domain which is smaller, but exists in all retroviruses. Pol is the domain that encodes the virion protease.
Retrovirus enters host cell
The retrovirus begins the journey into a host cell by attaching a surface glycoprotein to the cell's plasma membrane receptor. Once inside the cell, the retrovirus goes through reverse transcription in the cytoplasm and generates a double-stranded DNA copy of the RNA genome. Reverse transcription also produces identical structures known as long terminal repeats (LTRs). Long terminal repeats are at the ends of the DNA strands and regulates viral gene expression. The viral DNA is then translocated into the nucleus where one strand of the retroviral genome is put into the chromosomal DNA by the help of the virion intergrase. At this point the retrovirus is referred to as provirus. Once in the chromosomal DNA, the provirus is transcribed by the cellular RNA polymerase II. The transcription leads to the splicing and full-length mRNAs and full-length progeny virion RNA. The virion protein and progeny RNA assemble in the cytoplasm and leave the cell, whereas the other copies send translated viral messages in the cytoplasm.
- Human papilloma virus (HPV), a DNA virus, causes transformation in cells through interfering with tumor suppressor proteins such as p53. Interfering with the action of p53 allows a cell infected with the virus to move into a different stage of the cell cycle, enabling the virus genome to be replicated. Forcing the cell into the S phase of the cell cycle could cause the cell to become transformed. Some types of HPV increase the risk of, e.g., cervical cancer.
- Kaposi's sarcoma-associated herpesvirus (KSHV or HHV-8) is associated with Kaposi’s sarcoma, a type of skin cancer.
- Epstein–Barr virus (EBV or HHV-4) is associated with four types of cancers
- Merkel cell polyomavirus – a polyoma virus – is associated with the development of Merkel cell carcinoma
- Human cytomegalovirus (CMV or HHV-5) is associated with mucoepidermoid carcinoma and possibly other malignancies.
Not all oncoviruses are DNA viruses. Some RNA viruses have also been associated such as the hepatitis C virus as well as certain retroviruses, e.g., human T-lymphotropic virus (HTLV-1) and Rous sarcoma virus (RSV).
|Virus||Percent of cancers||Associated cancer types|
|Hepatitis B virus (HBV)||Hepatocarcinoma|
|Hepatitis C virus (HCV)||HCV is a known carcinogen, causing hepatocarcinoma|
|Human T-lymphotropic virus (HTLV)||0.03||Adult T-cell leukemia|
|Human papillomaviruses (HPV)||5.2||The types 16 and 18 are associated with cancers of cervix, anus, penis, vulva/vagina, and oropharyngeal cancer. According to statistics in the United States, females are more impacted by HPV-associated cancers (83%) than males (74%).|
|Kaposi's sarcoma-associated herpesvirus (HHV-8)||0.9||Kaposi’s sarcoma, multicentric Castleman's disease and primary effusion lymphoma|
|Merkel cell polyomavirus (MCV)||NA||Merkel cell carcinoma|
|Epstein–Barr virus (EBV)||NA||Burkitt's lymphoma, Hodgkin’s lymphoma, post-transplant lymphoproliferative disease, nasopharyngeal carcinoma and a subtype of stomach cancer.|
Estimated percent of new cancers attributable to the virus worldwide in 2002. NA indicates not available. The association of other viruses with human cancer is continually under research.
- Infectious causes of cancer
- Adult T-cell leukemia/lymphoma
- Cancer bacteria
- Oncolytic virus, a virus that infects and kills cancer cells
- Gag-onc fusion protein
- List of infectious diseases
- Valladares Y (1960). "Studies on cancerous pathogenesis. Production of leukemia and polycythemia vera by means of cancerous nucleoproteins from tissue cultures". Med Exp Int J Exp Med. 2: 309–16. doi:10.1159/000134890. PMID 13779782.
Herberman, Ronald B. (2012). "12: Immunology of Oncornaviruses". In Nahmias, André J.; O'Reilly, Richard J. (eds.). Immunology of Human Infection: Part II: Viruses and Parasites; Immunodiagnosis and Prevention of Infectious Diseases. Comprehensive Immunology. 9 (reprint ed.). New York: Plenum Publishing Corporation. pp. 273, 275. ISBN 9781468410129. Retrieved 2016-10-20.
Viruses known as oncogenic RNA viruses or oncornaviruses have been described in a wide variety of vertebrate species [...] there have been very few, if any, completely convincing examples of isolation of human oncornaviruses.
- Parkin DM (June 2006). "The global health burden of infection-associated cancers in the year 2002". Int. J. Cancer. 118 (12): 3030–44. doi:10.1002/ijc.21731. PMID 16404738.
- Marc Zapatka, Ivan Borozan, Daniel S. Brewer, Murat Iskar, Adam Grundhoff, Malik Alawi, Nikita Desai, Holger Sültmann, Holger Moch, PCAWG Pathogens, Colin S. Cooper, Roland Eils, Vincent Ferretti, Peter Lichter, PCAWG Consortium (February 2020). "The landscape of viral associations in human cancers". Nature Genetics. 52 (3): 320–330. doi:10.1038/s41588-019-0558-9. PMID 32025001.CS1 maint: uses authors parameter (link)
- Fredricks DN, Relman DA (January 1996). "Sequence-based identification of microbial pathogens: a reconsideration of Koch's postulates". Clin. Microbiol. Rev. 9 (1): 18–33. doi:10.1128/CMR.9.1.18. PMC 172879. PMID 8665474.
- Hill AB (May 1965). "The Environment and Disease: Association or Causation?". Proceedings of the Royal Society of Medicine. 58 (5): 295–300. doi:10.1177/003591576505800503. PMC 1898525. PMID 14283879.
- Parsonnet, Julie (1999). Microbes and malignancy: infection as a cause of human cancers. Oxford: Oxford University Press. ISBN 978-0-19-510401-1.[page needed]
- Choi, HS; Jain, V; Krueger, B; Marshall, V; Kim, CH; Shisler, JL; Whitby, D; Renne, R (2015). "Kaposi's Sarcoma-Associated Herpesvirus (KSHV) Induces the Oncogenic miR-17-92 Cluster and Down-Regulates TGF-β Signaling". PLOS Pathogens. 11 (11): e1005255. doi:10.1371/journal.ppat.1005255. PMC 4636184. PMID 26545119.
- Ellermann V.; Bang O. (1908). "Experimentelle Leukämie bei Hühnern". Zentralbl. Bakteriol. Parasitenkd. Infectionskr. Hyg. Abt. Orig. 46: 595–609.
- Rous P (April 1911). "A sarcoma of the fowl transmissible by an agent separable from the tumor cells". J. Exp. Med. 13 (4): 397–411. doi:10.1084/jem.13.4.397. PMC 2124874. PMID 19867421.
- Van Epps HL (February 2005). "Peyton Rous: father of the tumor virus". J. Exp. Med. 201 (3): 320. doi:10.1084/jem.2013fta. PMC 2213042. PMID 15756727.
- Bittner JJ (May 1942). "The Milk-Influence of Breast Tumors in Mice". Science. 95 (2470): 462–463. Bibcode:1942Sci....95..462B. doi:10.1126/science.95.2470.462. PMID 17736889.
- Lathrop AE, Loeb L (November 1915). "Further Investigations on the Origin of Tumors in Mice: I. Tumor Incidence and Tumor Age in Various Strains of Mice". The Journal of Experimental Medicine. 22 (5): 646–673. doi:10.1084/jem.22.5.646. PMC 2125363. PMID 19867946.
- Friend C (1957). "Cell-free transmission in adult Swiss mice of a disease having the character of a leukemia". J Exp Med. 105 (4): 307–18. doi:10.1084/jem.105.4.307. PMC 2136697. PMID 13416470.
- Tontonoz, Matthew (2019-03-13). "From Controversy to Consensus: How Charlotte Friend Changed Cancer Biology". Memorial Sloan Kettering Cancer Center. Retrieved 2019-04-18.
- Carroll-Pankhurst C, Engels EA, Strickler HD, Goedert JJ, Wagner J, Mortimer EA (November 2001). "Thirty-five year mortality following receipt of SV40- contaminated polio vaccine during the neonatal period". Br. J. Cancer. 85 (9): 1295–7. doi:10.1054/bjoc.2001.2065. PMC 2375249. PMID 11720463.
- Shah KV (January 2007). "SV40 and human cancer: a review of recent data". Int. J. Cancer. 120 (2): 215–23. doi:10.1002/ijc.22425. PMID 17131333.
- Epstein MA, Achong BG, Barr YM (March 1964). "Virus Particles in Cultured Lymphoblasts from Burkitt's Lymphoma". Lancet. 1 (7335): 702–3. doi:10.1016/S0140-6736(64)91524-7. PMID 14107961.
- "Baruch S. Blumberg - Autobiography". Nobelprize.org. Retrieved 2010-03-17.
- Beasley RP, Hwang LY, Lin CC, Chien CS (November 1981). "Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan". Lancet. 2 (8256): 1129–33. doi:10.1016/S0140-6736(81)90585-7. PMID 6118576.
- Yoshida, Mitsuaki; Jeang, Kuan-Teh (2005). "Preface to 25 years of HTLV-1 and ATL research". Oncogene. 24 (39): 5925. doi:10.1038/sj.onc.1208967.
- Gallo RC (September 2005). "History of the discoveries of the first human retroviruses: HTLV-1 and HTLV-2". Oncogene. 24 (39): 5926–30. doi:10.1038/sj.onc.1208980. PMID 16155599.
- Seiki M, Hattori S, Yoshida M (November 1982). "Human adult T-cell leukemia virus: molecular cloning of the provirus DNA and the unique terminal structure". Proceedings of the National Academy of Sciences of the United States of America. 79 (22): 6899–902. Bibcode:1982PNAS...79.6899S. doi:10.1073/pnas.79.22.6899. PMC 347241. PMID 6294664.
- "Harald zur Hausen - Autobiography". Nobelprize.org. Retrieved 2010-03-17.
- Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M (April 1989). "Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome". Science. 244 (4902): 359–62. Bibcode:1989Sci...244..359C. doi:10.1126/science.2523562. PMID 2523562.
- Schmidt C (April 2008). "Yuan Chang and Patrick Moore: teaming up to hunt down cancer-causing viruses". J. Natl. Cancer Inst. 100 (8): 524–5, 529. doi:10.1093/jnci/djn122. PMID 18398088.
- "Ethel Cesarman, M.D., Ph.D. | Weill Cornell Medical College". Med.cornell.edu. Retrieved 2010-03-17.
- Beral V, Peterman TA, Berkelman RL, Jaffe HW (January 1990). "Kaposi's sarcoma among persons with AIDS: a sexually transmitted infection?". Lancet. 335 (8682): 123–8. doi:10.1016/0140-6736(90)90001-L. PMID 1967430.
- Antman K, Chang Y (April 2000). "Kaposi's sarcoma". The New England Journal of Medicine. 342 (14): 1027–38. doi:10.1056/NEJM200004063421407. PMID 10749966.
- Feng H, Taylor JL, Benos PV, et al. (October 2007). "Human Transcriptome Subtraction by Using Short Sequence Tags To Search for Tumor Viruses in Conjunctival Carcinoma". Journal of Virology. 81 (20): 11332–40. doi:10.1128/JVI.00875-07. PMC 2045575. PMID 17686852.
- Feng H, Shuda M, Chang Y, Moore PS (February 2008). "Clonal integration of a polyomavirus in human Merkel cell carcinoma". Science. 319 (5866): 1096–100. Bibcode:2008Sci...319.1096F. doi:10.1126/science.1152586. PMC 2740911. PMID 18202256.
- Ellerman C, Bang O (1908). "Experimentelle Leukämie bei Hühnern". Zentralbl. Bakteriol. Parasitenkd. Infectionskr. Hyg. Abt. Orig. 46: 595–609.
- Rous, Peyton (1910). "A Transmissible Avian Neoplasm (Sarcoma of the Common Fowl)". Journal of Experimental Medicine. 12 (5): 696–705. doi:10.1084/jem.12.5.696. PMC 2124810. PMID 19867354.
- Ben David Y, Prideaux VR, Chow V, Benchimol S, Bernstein A (1988). "Inactivation of the p53 oncogene by internal deletion or retroviral integration in erythroleukemic cell lines induced by Friend leukemia virus". Oncogene. 3 (2): 179–85. PMID 2842714.
- zur Hausen H (November 1991). "Viruses in human cancers". Science. 254 (5035): 1167–73. Bibcode:1991Sci...254.1167Z. doi:10.1126/science.1659743. PMID 1659743.
- Mantovani F, Banks L (November 2001). "The human papillomavirus E6 protein and its contribution to malignant progression". Oncogene. 20 (54): 7874–87. doi:10.1038/sj.onc.1204869. PMID 11753670.
- Felsani A, Mileo AM, Paggi MG (August 2006). "Retinoblastoma family proteins as key targets of the small DNA virus oncoproteins". Oncogene. 25 (38): 5277–85. doi:10.1038/sj.onc.1209621. PMID 16936748.
- Gaston, K, eds. (2012). Small DNA Tumor Viruses. Caister Academic Press. ISBN 978-1-904455-99-8.
- Poulin DL, DeCaprio JA (September 2006). "Is there a role for SV40 in human cancer?". J. Clin. Oncol. 24 (26): 4356–65. doi:10.1200/JCO.2005.03.7101. PMID 16963733.
- Wiest T, Schwarz E, Enders C, Flechtenmacher C, Bosch FX (February 2002). "Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control". Oncogene. 21 (10): 1510–7. doi:10.1038/sj.onc.1205214. PMID 11896579.
- Sambrook J, Greene R, Stringer J, Mitchison T, Hu SL, Botchan M (1980). "Analysis of the sites of integration of viral DNA sequences in rat cells transformed by adenovirus 2 or SV40". Cold Spring Harb. Symp. Quant. Biol. 44 (1): 569–84. doi:10.1101/sqb.1980.044.01.059. PMID 6253158.
- Morgan, D. O. (2007). The cell cycle: principles of control. New Science Press. ISBN 978-1-904455-99-8.
- Levine AJ (February 2009). "The common mechanisms of transformation by the small DNA tumor viruses: The inactivation of tumor suppressor gene products: p53". Virology. 384 (2): 285–93. doi:10.1016/j.virol.2008.09.034. PMID 19081592.
- DeCaprio JA (February 2009). "How the Rb tumor suppressor structure and function was revealed by the study of Adenovirus and SV40". Virology. 384 (2): 274–84. doi:10.1016/j.virol.2008.12.010. PMID 19150725.
- Scheffner M, Huibregtse JM, Vierstra RD, Howley PM (November 1993). "The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53". Cell. 75 (3): 495–505. doi:10.1016/0092-8674(93)90384-3. PMID 8221889.
- Dyson N, Howley PM, Münger K, Harlow E (February 1989). "The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product". Science. 243 (4893): 934–7. Bibcode:1989Sci...243..934D. doi:10.1126/science.2537532. PMID 2537532.
- Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM (December 1990). "The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53". Cell. 63 (6): 1129–36. doi:10.1016/0092-8674(90)90409-8. PMID 2175676.
- Chang Y, Cesarman E, Pessin MS, et al. (December 1994). "Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma". Science. 266 (5192): 1865–9. Bibcode:1994Sci...266.1865C. doi:10.1126/science.7997879. PMID 7997879.
- Melnick M, Sedghizadeh PP, Allen CM, Jaskoll T (February 2012). "Human cytomegalovirus and mucoepidermoid carcinoma of salivary glands: cell-specific localization of active viral and oncogenic signaling proteins is confirmatory of a causal relationship". Exp. Mol. Pathol. 92 (1): 118–25. doi:10.1016/j.yexmp.2011.10.011. PMID 22101257.
- Tang, CM; Yau, TO; Yu, J (28 May 2014). "Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments". World Journal of Gastroenterology. 20 (20): 6262–78. doi:10.3748/wjg.v20.i20.6262. PMC 4033464. PMID 24876747.
- NTP (National Toxicology Program) (2016). Report on Carcinogens (Fourteenth ed.). Research Triangle Park, NC: U.S. Department of Health and Human Services, Public Health Service. Retrieved 8 January 2017.
- Bellon M, Nicot C (2007). "Telomerase: a crucial player in HTLV-I-induced human T-cell leukemia". Cancer Genomics & Proteomics. 4 (1): 21–5. PMID 17726237.
- Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S (September 2007). "Human papillomavirus and cervical cancer". Lancet. 370 (9590): 890–907. doi:10.1016/S0140-6736(07)61416-0. PMID 17826171.
- How Many Cancers Are Linked with HPV Each Year? CDC.gov
- Klein E, Kis LL, Klein G (February 2007). "Epstein-Barr virus infection in humans: from harmless to life endangering virus-lymphocyte interactions". Oncogene. 26 (9): 1297–305. doi:10.1038/sj.onc.1210240. PMID 17322915.
- Yau, TO; Tang, CM; Yu, J (7 June 2014). "Epigenetic dysregulation in Epstein-Barr virus-associated gastric carcinoma: disease and treatments". World Journal of Gastroenterology. 20 (21): 6448–56. doi:10.3748/wjg.v20.i21.6448. PMC 4047330. PMID 24914366.